ArticleJournal of the Pediatric Infectious Diseases Society2023
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
Article in Journal of the Pediatric Infectious Diseases Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pooled it
- A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.Clinical and translational science · 2025Trial
- Effectiveness of Nirsevimab Reimmunization against Respiratory Syncytial Virus Hospitalization During the Second Season in High-Risk Children.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Delineating RSV-A and RSV-B: Epidemiological Patterns, Diagnostics, Clinical Severity, and Preventive Approaches.Journal of medical virology · 2026Review
- Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Prevention of Respiratory Infections in Children with Congenital Heart Disease: Current Evidence and Clinical Strategies.Vaccines · 2025Review
- Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner.Human vaccines & immunotherapeutics · 2025Review
- [Expert consensus on monoclonal antibody immunoprophylaxis against respiratory syncytial virus in infants and young children in tropical and subtropical regions of China].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Article
- High seroprevalence and high risk: why are older adults more prone to respiratory syncytial virus?Journal of virology · 2025Review
- Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children.Clinical and experimental pediatrics · 2025Article
- RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions.JAMA network open · 2025Article
- Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.Open forum infectious diseases · 2025Review
- RSV: an overview of infection in adults.Pneumonia (Nathan Qld.) · 2025Review
- Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign.Vaccines · 2025Article
- Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan.Infectious diseases and therapy · 2025Article
- Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.BMJ public health · 2025Article
- Article
- Nirsevimab to reduce infant morbidity from respiratory syncytial virus.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.Pathogens (Basel, Switzerland) · 2024Article
- Formulary Drug Reviews: Nirsevimab.Hospital pharmacy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 7 countries.
Funding
Abstract
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.